The Law Offices of Vincent Wong
SHAREHOLDER ALERT: TEVA RBGLY CARB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Sunday, August 4, 2019 10:43 AM
NEW YORK, NY / ACCESSWIRE / August 4, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/teva-pharmaceutical-industries-ltd-loss-submission-form?prid=2750&wire=1.
Lead Plaintiff Deadline: August 23, 2019
Class Period: on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019.
Allegations against TEVA include that: (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.
Reckitt Benckiser Group plc (OTCPINK:RBGLY)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/reckitt-benckiser-group-plc-loss-submission-form?prid=2750&wire=1.
Lead Plaintiff Deadline: September 13, 2019
Class Period: On behalf of all purchasers of Reckitt American Depositary Shares (“ADSs”) from July 28, 2014 through April 9, 2019.
Allegations against RBGLY include that: (a) defendants had engaged in a scheme to artificially inflate the sales of Suboxone Film by more than $3 billion by falsely touting the drug’s purportedly superior efficacy and safety as compared to tablets; (b) contrary to defendants’ public statements, the FDA and internal Company documents had concluded that Suboxone Film posed a potentially greater risk of abuse and child endangerment than other available treatments; (c) defendants had fabricated a safety scare involving Suboxone Tablets in order to unlawfully delay and prevent generic competition; (d) defendants had engaged in a massive marketing campaign that had misrepresented the purported benefits of Suboxone Film as compared to Suboxone Tablets to doctors, healthcare providers, government regulators and investors; (e) defendants had encouraged Suboxone sales through medical providers that they knew were overprescribing the drug, facilitating the drug’s abuse and/or prescribing it in a careless and clinically unwarranted manner, often to hundreds of individuals at a time; (f) as a result of (a)-(e) above, Reckitt’s revenues, net income an d earnings were artificially inflated and the product of illicit business practices; and (g) as a result of (a)-(f) above, Reckitt and Reckitt Pharma were exposed to extraordinary undisclosed legal and reputational risks that could result in billions of dollars in fines, lost business and legal judgments or other monetary penalties.
Carbonite, Inc. (NASDAQ:CARB)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/carbonite-inc-loss-submission-form?prid=2750&wire=1.
Lead Plaintiff Deadline: September 30, 2019
Class Period: February 7, 2019 to July 25, 2019
Allegations against CARB include that: (i) Carbonite’s Server Backup VM Edition was of poor quality and technologically flawed; (ii) Carbonite was receiving poor reviews and complaints from customers about the Server Backup VM Edition; (iii) the poor quality and technological flaws of the Server Backup VM Edition was acting as a “disruptive” factor throughout the Carbonite salesforce and keeping that sales organization from closing opportunistically on several larger deals during fiscal 2019; and (iv) as a result of the foregoing, Carbonite lacked any reasonable for issuing its positive projections and financial forecasts.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong